Kimberly H. Johnson, an insider at Eli Lilly and Co (LLY), acquired 3,265 shares of the company on November 16, 2025, at a price of $1,021.70 per share. The total transaction value reached approximately $3.34 million.
Following this purchase, Johnson holds a total of 3,265 shares in Eli Lilly. The company, headquartered in Indianapolis, Indiana, is a leading player in the pharmaceuticals industry, employing 47,000 full-time staff. Eli Lilly specializes in the discovery, development, manufacture, and sale of a wide range of pharmaceutical products, including treatments for cardiometabolic health, oncology, immunology, and neuroscience.
Eli Lilly's current market capitalization stands at $965.9 billion, with a P/E ratio of 52.46 and an EPS of 20.45. The company also offers a dividend yield of 58.7%. Upcoming earnings reports are scheduled for April 28, 2026, with an estimated EPS of $7.16 and revenue of $17.1 billion, followed by another report on August 4, 2026, with an EPS estimate of $7.86 and revenue of $18.7 billion.
Insider transactions like this one are reported to the SEC, providing transparency into how executives view their company's stock. While such buying activity can be seen as a positive indicator, investors are advised to consider it alongside other fundamental and technical factors to make informed decisions.